Key clinical point: For older patients with CD-33 positive AML, vadastuximab talirine plus a hypomethylating agent improves remission rates.
Major finding: The composite remission rate in patients treated with vadastuximab talirine and HMA therapy was 70%, compared with 17.8%-27.8% for patients treated with HMA therapy alone historically.
Study details: A prospective, phase 1 trial involving 53 elderly patients with CD33-positive AML at 14 treatment centers.
Disclosures: Seattle Genetics provided study funding and author compensation.
Fathi AT et al. Blood. 2018 Jul 25. doi: 10.1182/blood-2018-03-841171.
Must Reads in AML
IDH-mutated AML: First-line IDH inhibitors, chemo may up remission, Stein EM et al. ASH 2018, Abstract 560
Rapid genomic results possible, Beat AML trial suggests, Burd A et al. ASH 2018, Abstract 559
Phase 2 results for combo therapy in relapsed AML, Daver N et al. Cancer Discov. 2018 Nov 8. doi: 10.1158/2159-8290.CD-18-0774